MediWound Ltd. announced the appointment of Barry Wolfenson as Executive Vice President of Strategy & Corporate Development. In this role, Mr. Wolfenson will be responsible for the Company's global strategic plan, business development and initiatives to generate overall growth. MediWound also announced the appointment of Alicia Torrenova, as Vice President of European Operations.

Mr. Wolfenson co-founded and is also CEO of vTail Healthcare Telecommunications, a healthcare-wide digital platform with an initial focus on the advanced wound care market. He also recently served as a key Strategic Advisor to Origin Inc. on the development of their Phase III-ready IonoJetTM technology with an initial indication of diabetic foot ulcers. Mr. Wolfenson is currently on the Board of Directors at SANO Diagnostics, after having served as their CEO.

SANO Diagnostics is a point-of-care inflammation diagnostic platform with initial focus on chronic wounds. Mr. Wolfenson spent 13 years at Derma Sciences in roles of increasing responsibility, helping to build the company's advanced wound care business prior to its acquisition by Integra Life Sciences. He began his career as an analyst at Accenture before moving on to roles at Bristol Myers Squibb.

Mr. Wolfenson holds a Master of Business Administration from the Stephen M. Ross School of Business, University of Michigan. He holds a Bachelor of Arts in Economics, & Pre-Med from Franklin & Marshall College.